medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Número 2

<< Anterior Siguiente >>

Arch Neurocien 2023; 28 (2)


Therapeutic potential of cannabinoids for stroke: scoping review protocol

Pérez-Neri I, Estêvão MD, Mishra R, Sandoval H, Zárate M, Ríos C

Idioma: Ingles.
Referencias bibliográficas: 39
Paginas: 28-34
Archivo PDF: 240.72 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. United Nations Office on Drugs and Crime. World Drug Report 2021. United Nations publication, Sales No. E.21.XI.8; 2021.doi: 10.18356/9789210058032

  2. Tournebize J, Gibaja V, Kahn JP. Acute effects of syntheticcannabinoids: Update 2015. Subst Abus. 2017;38(3):344-66.

  3. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS,Callaway CW, et al. Heart disease and stroke statistics-2021update: A report from the American Heart Association.Circulation. 2021;143(8):e254-e743.doi:10.1161/CIR.0000000000000950

  4. Nelson S, Whitsel L, Khavjou O, Phelps D, Leib A. Projections ofcardiovascular disease prevalence and costs: 2015–2035. RTIInternational; 2016.

  5. Stewart C, Subbarayan S, Paton P, Gemmell E, Abraha I, Myint PK,et al. Non-pharmacological interventions for the improvementof post-stroke quality of life amongst older stroke survivors:a systematic review of systematic reviews. Eur Geriatr Med.2019;10(3):359-86. doi: 10.1007/s41999-019-00180-6

  6. Zarruk JG, Fernández-López D, García-Yébenes I, García-Gutiérrez MS, Vivancos J, Nombela F, et al. Cannabinoid type2 receptor activation downregulates stroke-induced classic andalternative brain macrophage/microglial activation concomitantto neuroprotection. Stroke. 2012;43(1):211-9. doi: 10.1161/STROKEAHA.111.631044

  7. Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is thecurrent knowledge about the cardiovascular risk for users ofcannabis-based products? A systematic review. Curr AtherosclerRep. 2017;19(6):26. doi: 10.1007/s11883-017-0663-0

  8. Yoo SGK, Seth M, Vaduganathan M, Ruwende C, Karve M,Shah I, et al. Marijuana use and in-hospital outcomes afterpercutaneous coronary intervention in Michigan, UnitedStates. JACC Cardiovasc Interv. 2021;14(16):1757-67. doi:10.1016/j.jcin.2021.06.036

  9. Gómez Ochoa SA. Stroke and cannabis use in patients with nocardiovascular risk factors: a systematic review of case reports.Neurologia (Engl Ed). 2021;36(3):222-8. doi: 10.1016/j.nrl.2017.09.016

  10. Chiu RG, Fuentes AM, Patil SN, Chiu R, McGuire LS, MehtaAI. Cannabis abuse and perioperative complications aftertreatment of intracranial aneurysms: A nationwide analysis.World Neurosurg. 2022 Feb;158:e184-e195. doi: 10.1016/j.wneu.2021.10.156

  11. Rabat Y, Sibon I, Berthoz S. Implication of problematic substanceuse in poststroke depression: An hospital-based study. Sci Rep.2021;11(1):13324. doi: 10.1038/s41598-021-92639-5

  12. Gorelick DA, Hermann R. Cannabis use and disorder:Epidemiology, comorbidity, health consequences, and medicolegalstatus. UpToDate. 2020; 20172-150:1-36.

  13. England TJ, Hind WH, Rasid NA, O’Sullivan SE. Cannabinoidsin experimental stroke: A systematic review and meta-analysis. JCereb Blood Flow Metab. 2015;35(3):348-58. doi: 10.1038/jcbfm.2014.218

  14. Marinelli L, Balestrino M, Mori L, Puce L, Rosa GM, GiorelloL, et al. A randomised controlled cross-over double-blindpilot study protocol on THC: CBD oromucosal spray efficacyas an add-on therapy for post-stroke spasticity. BMJ open.2017;7(9):e016843. DOI: 10.1136/bmjopen-2017-016843

  15. Moser U. Tetrahydrocannabinol and cannabidiol as anoromucosal spray in a 1: 1 ratio: a therapeutic option for patientswith central post-stroke pain syndrome. BMJ Case Reports CP.2021;14(7):e243072. doi: 10.1136/bcr-2021-243072

  16. Hashiesh HM, Jha NK, Sharma C, Gupta PK, Jha SK, Patil CR, etal. Pharmacological potential of JWH133, a cannabinoid type 2receptor agonist in neurodegenerative, neurodevelopmental andneuropsychiatric diseases. Eur J Pharmacol. 2021;909:174398.

  17. Sultan SR, Millar SA, England TJ, O’Sullivan SE. A systematicreview and meta-analysis of the haemodynamic effects ofcannabidiol. Front Pharmacol. 2017;8:81. doi: 10.3389/fphar.2017.00081

  18. Wang LN, Xing MD, Qu WT, Wang CB, Liu ZQ, Han J, et al.Impaired vessel relaxation response and increased infarct size insmooth muscle cannabinoid receptor 1 knockout mice. MicrovascRes. 2022;139:104263. doi: 10.1016/j.mvr.2021.104263

  19. Davis MP, Behm B, Mehta Z, Fernandez C. The Potential Benefitsof Palmitoylethanolamide in Palliation: A Qualitative SystematicReview. Am J Hosp Palliat Care. 2019;36(12):1134-54. doi:10.1177/1049909119850807

  20. Annunziata C, Pirozzi C, Lama A, Senzacqua M, Comella F,Bordin A, et al. Palmitoylethanolamide promotes white-tobeigeconversion and metabolic reprogramming of adipocytes:Contribution of PPAR-α. Pharmaceutics. 2022;14(2):338. doi:10.3390/pharmaceutics14020338

  21. Azar S, Udi S, Drori A, Hadar R, Nemirovski A, Vemuri KV, etal. Reversal of diet-induced hepatic steatosis by peripheral CB1receptor blockade in mice is p53/miRNA-22/SIRT1/PPARαdependent. Mol Metab. 2020;42:101087.

  22. Pérez-Neri I, Diéguez-Campaa CE, Sandoval H, ChávezVA, Castro-Martínez E, Ríos C. Therapeutic potential ofdehydroepiandrosterone for Parkinson’s disease: scoping reviewprotocol. Arch Neurocien. 2022;27(2):39-46. doi: 10.31157/an.v27i2.331

  23. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’s disease inRomania: A scoping review protocol. Brain Sci. 2021;11(2):251.

  24. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G,Buttery SC, Chynkiamis N, et al. Walking-related digital mobilityoutcomes as clinical trial endpoint measures: protocol fora scoping review. BMJ Open. 2020;10(7):e038704. doi:10.1136/bmjopen-2020-038704.

  25. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis.JBI; 2020.

  26. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, MulrowCD, et al. PRISMA 2020 explanation and elaboration: Updatedguidance and exemplars for reporting systematic reviews. BMJ.2021;372:n160. doi: 10.1136/bmj.n160

  27. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H,Chalmers I, et al. PRISMA for Abstracts: reporting systematicreviews in journal and conference abstracts. PLoS Med.2013;10(4):e1001419. doi: 10.1371/journal.pmed.1001419

  28. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, PetticrewM, et al. Preferred reporting items for systematic review andmeta-analysis protocols (PRISMA-P) 2015: elaboration andexplanation. BMJ. 2015;350:g7647. doi: 10.1136/bmj.g7647

  29. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D,Page MJ, et al. PRISMA-S: an extension to the PRISMA Statementfor Reporting Literature Searches in Systematic Reviews. Syst Rev.2021;10(1):39. doi: 10.1186/s13643-020-01542-z.

  30. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist andexplanation. Ann Intern Med. 2018;169(7):467-73. doi: 10.7326/M18-0850

  31. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studiesreporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147-53. doi: 10.1097/XEB.0000000000000054

  32. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015Guideline Statement. J Clin Epidemiol. 2016;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021

  33. Bramer WM, de Jonge GB. Improving efficiency and confidence in systematic literature searching. Workshop given at InternationalCongress of Medical Librarianship (ICML) & European Association for Health Information and Libraries (EAHIL). Dublin; 2017:1-16.

  34. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID -19. Clin Exp Optom.2020;103(4):418-44. doi: 10.1111/cxo.13088

  35. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C, Ríos C. Therapeutic potential of ultrasound neuromodulation in decreasingneuropathic pain: Clinical and experimental evidence. Curr Neuropharmacol. 2021;19(3):334-48. doi: 10.2174/1570159X18666200720175253

  36. McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicatingreferences. Syst Rev. 2021;10(1):38. doi: 10.1186/s13643-021-01583-y

  37. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J, Luechtefeld T. Sysrev: A FAIR platform for data curation and systematic evidencereview. Front Artif Intell. 2021;4:685298. doi: 10.3389/frai.2021.685298

  38. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group offersevidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13-22. doi: 10.1016/j.jclinepi.2020.10.007

  39. Usher R, Stapleton T. Approaches for assessing decision-making capacity in older adults: a scoping review protocol. JBI Evidence Synthesis.2020;18(4):832-40. doi: 10.11124/JBISRIR-D-19-00068




2020     |     www.medigraphic.com